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Review
The trend toward earlier breast develop  ment 
initiation in U.S. girls (Euling et al. 2008) 
may put them at increased risk of later life out­
comes such as breast cancer—already the most 
common cancer in U.S. women (American 
Cancer Society 2010) and a leading cause of 
death for U.S. women in midlife (Brody et al. 
2007). Although many factors, such as nutri­
tional status and body size, may contribute to 
maturation trends (Kaplowitz 2008) and breast 
cancer (Renehan et al. 2008), environmen­
tal chemicals have been hypothesized to con­
tribute as well (Birnbaum and Fenton 2003; 
Brody et al. 2007; Euling et al. 2008). Animal 
studies demon  strate that early life exposure to 
hormonally active agents can lead to effects on 
mammary gland (MG) develop  ment, impaired 
lactation, and increased susceptibility to can­
cer (Fenton 2006). However, the influence of 
environmental exposures on breast develop­
ment outcomes is poorly understood, as is 
the relationship between breast develop  ment, 
lactational deficits, and breast cancer. Few 
chemicals coming into the marketplace are 
evaluated for these effects. The findings in ani­
mal studies raise concerns that perturbations 
to human breast develop  ment may increase 
the risk for later life adverse effects including 
lactation impairment, gynecomastia (in males), 
and breast cancer in either sex.
This review is the result of the Mammary 
Gland Evaluation and Risk Assessment 
Workshop held in Oakland, California, 
USA, on 16–17 November 2009 to review 
and discuss recent findings of altered MG 
develop  ment after gestational/perinatal expo­
sure to certain endocrine­disrupting chemi­
cals (EDCs). Workshop participants included 
research scientists from multiple disciplines, 
public health advocates, and risk assessors. 
Many of the participants are leading interna­
tionally recognized MG experts.
The goal of the workshop was to improve 
assessment of MG develop  mental end points 
and their integration into human health risk 
assessment. Workshop participants discussed 
current research on the effects of develop­
mental exposures to EDCs on MG develop­
ment, the relationship of these effects to later 
life lactation and cancer outcomes, relative 
sensitivity of MG develop  ment and other 
develop  mental reproductive end points, rele­
vance of effects in animal models to humans, 
and MG assessment in current toxicology pro­
tocols. Data gaps and research recommen­
dations were identified at the workshop and 
through interviews with 18 risk assessors and 
toxicologists. Presentation slides and other 
workshop materials are available online (Silent 
Spring Institute 2011). In conjunction with 
the workshop, experts from seven labora  tories 
in Canada, the United States, and Argentina 
participated in a round­robin evaluation of 
MG whole mounts.
Factors Affecting Mammary 
Gland Development
The female MG undergoes most of its 
develop  ment postnatally, achieving a fully 
differentiated state late in pregnancy. This 
process includes numerous events that can be 
disrupted by exposure to EDCs. Gestation, 
puberty, and pregnancy are the critical periods 
during which EDC exposure may most affect 
MG develop  ment (Fenton 2006). Critical 
events include mammary bud develop  ment 
in the fetus, exponential epithelial outgrowth 
during puberty, and the rapid transition to 
lactational competency that occurs during 
late pregnancy (Figure 1). These stages occur 
in both rodents and humans.
Normal MG develop  ment. Normal female 
MG develop  ment involves a well­orchestrated 
sequence of events marked by extensive pro­
liferation at puberty and by proliferation and 
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Objectives: Perturbations in mammary gland (MG) develop  ment may increase risk for later 
adverse effects, including lactation impairment, gynecomastia (in males), and breast cancer. Animal 
studies indicate that exposure to hormonally active agents leads to this type of develop  mental effect 
and related later life susceptibilities. In this review we describe current science, public health issues, 
and research recommendations for evaluating MG develop  ment.
Da t a s O u r c e s: The Mammary Gland Evaluation and Risk Assessment Workshop was convened 
in Oakland, California, USA, 16–17 November 2009, to integrate the expertise and perspectives of 
scientists, risk assessors, and public health advocates. Interviews were conducted with 18 experts, 
and seven laboratories conducted an MG slide evaluation exercise. Workshop participants discussed 
effects of gestational and early life exposures to hormonally active agents on MG develop  ment, the 
relationship of these develop  mental effects to lactation and cancer, the relative sensitivity of MG 
and other develop  mental end points, the relevance of animal models to humans, and methods for 
evaluating MG effects.
sy n t h e s i s : Normal MG develop  ment and MG carcinogenesis demonstrate temporal, morphologi­
cal, and mechanistic similarities among test animal species and humans. Diverse chemicals, includ­
ing many not considered primarily estrogenic, alter MG develop  ment in rodents. Inconsistent 
reporting methods hinder comparison across studies, and relationships between altered develop­
ment and effects on lactation or carcinogenesis are still being defined. In some studies, altered MG 
develop  ment is the most sensitive endocrine end point.
cO n c l u s i O n s: Early life environmental exposures can alter MG develop  ment, disrupt lactation, and 
increase susceptibility to breast cancer. Assessment of MG develop  ment should be incorporated in 
chemical test guidelines and risk assessment.
Key w O r D s : breast cancer, carcinogen susceptibility, develop  ment, endocrine disruptors, human 
health, lactation, mammary gland, risk assessment, rodent model, whole mount. Environ Health 
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differentiation during pregnancy. This process 
is regulated by hormones, growth factors, and 
stromal factors and is similar between rodents 
and humans, although rodent MG develop­
ment is more completely described (Kleinberg 
et al. 2009; Medina 2005). Female human 
MG develop  ment begins with budding and 
branching between 6 and 20 weeks of gesta­
tion, yielding at birth a primitive gland com­
posed of ducts ending in ductules. During 
childhood, MG growth keeps pace with 
overall body growth; at puberty it accelerates 
  dramatically.
In rodents, the epithelial bud is formed 
at the site of the nipple around gestation days 
(GDs) 12–16, and by birth the epithelium 
has entered the fat pad and formed a ductal 
tree. The fat pad and mammary epithelium 
grow at the same pace as the body for the first 
2–3 weeks of life, and just before puberty, an 
exponential growth phase begins. In rodents, 
and presumably in humans, this phase of duc­
tal develop  ment is characterized by formation 
of terminal end buds (TEBs), which lead the 
epithelial extension through the fat pad, leav­
ing behind a network of branched ducts. After 
the fat pad is filled, TEBs differentiate into 
terminal ductal structures, namely, terminal 
ductal lobular units in humans, lobules and 
alveolar buds in rats, and terminal ducts in 
mice. In humans and rodents, additional MG 
proliferation and regression events occur with 
each luteal phase of the ovulatory cycle, and 
at pregnancy there is significant differentia­
tion of the terminal structures with lobular–
alveolar develop  ment (Kleinberg et al. 2009; 
Russo and Russo 2004a, 2004b). Mammary 
epithelial growth also occurs in male rats and 
men, whereas male mice lack mammary epi­
thelium. Male mice and rats do not normally 
possess nipples because androgens during ges­
tation induce regression. Retained nipples in 
male rats is a charac  teris  tic effect of pre  natal 
anti  androgen exposure (Foley et al. 2001).
Assessment of altered MG develop  ment. 
Whole mounts and other techniques. Early 
life treatment with some hormonally active 
agents results in altered develop  ment of the 
MG in male and female rodents. Although 
laboratories vary in their methods for report­
ing altered MG develop  ment, the primary 
approach has been morphological assess­
ment of the entire fourth or fifth abdominal 
MG fat pad mounted flat on a slide, fixed, 
stained, defatted, and permanently affixed 
to the slide as a “whole mount.” Whole 
mounts allow an assessment of total and rela­
tive abundance of mammary terminal ductal 
structures (i.e., TEBs, terminal ducts, alveolar 
buds, and lobules), extension of the epithelial 
cells through the fat pad, and branching pat­
terns and density at different times during 
develop  ment [e.g., Fenton et al. 2002; see also 
Supplemental Material, Table 1 (doi:10.1289/
ehp.1002864)]. A common measurement in 
mammary whole mounts is the number of 
TEBs. A TEB is a teardrop­shaped duct end 
with a diameter of about 100 µm in the rat 
compared with about 70 µm for a terminal 
duct (Russo and Russo 1978).
Several rodent studies have reported altered 
MG develop  ment after pre  natal, neo  natal, or 
Figure 1. Stages of normal rat MG development and effects of environment on subsequent events. Effects of early life EDC exposures can lead to altered develop-
mental programming in the breast and have been reported neonatally, at puberty, and well into adulthood, when effects on lactation or mammary tumorigenesis 
become evident. The normal morphology and pace of pubertal development are often altered, and these effects can be observed using MG whole-mount prepara-
tions. Transient or permanent effects may be due to gene imprinting, altered gene expression, modified endogenous MG signaling, or changes in hormonal milieu. 
Arrows indicate plausible (black) or more certain (gray) mechanistic pathways. Photomicrographs for early life and puberty were all taken at 16× magnification on 
a macroscope (adapted from Enoch et al. 2007, with permission from Environmental Health Perspectives); photo  micrographs for pregnancy/lactation and adult-
hood were taken at 10× magnification on a standard microscope (from S.E.F.). Bars = 2 mm. 
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peri  pubertal exposure to a range of hormon­
ally active agents, including pharmaceutical 
hormones, dietary constituents, and EDCs [see 
Supplemental Material, Table 1 (doi:10.1289/
ehp.1002864)]. These studies typically include 
histo  pathological evaluation of MG whole 
mounts of developing animals and report mor­
phological features such as branching, extent 
of growth, and relative proportion of struc­
tures (e.g., TEBs, lobules, and terminal ducts). 
Other studies report changes in morphology 
or immuno  histochemistry of tissue sections 
or gene expression in tissue homogenates. 
Methods and data reporting vary between labo­
ratories, making it difficult to compare findings 
across studies. More uniform approaches will 
facilitate progress; however, unanticipated end 
points should continue to be reported because 
this field is still developing.
Morphological changes reflect timing   
of assessment. Because normal develop­
ment involves a well­characterized, consistent 
progression of types and ratios of terminal 
structures and extension through the fat pad, 
alterations are sometimes reported as acceler­
ated or delayed develop  ment relative to con­
trols (e.g., Moon et al. 2007). Some agents 
alter the pace at which differentiation occurs, 
leading to an increased or decreased number 
of TEBs depending on timing of assessment. 
If a peri  natally administered EDC causes 
accelerated develop  ment, the number of TEBs 
in the treated group will be higher than that 
in vehicle­treated controls at weaning [post­
natal day (PND) 21] because of increased 
proliferation, but lower in early adulthood 
(PNDs 45–50) because of accelerated differ­
entiation, as is seen after exposure to estrogens 
(Hovey et al. 2005). In the case of an EDC, 
such as dioxin, that causes delayed develop­
ment, reduced differentiation leads to a higher 
number of TEBs in early adulthood and a 
longer period during which TEBs are present 
(Brown et al. 1998; Fenton et al. 2002). The 
number of TEBs present in the gland also 
depends on the number of ducts in the gland. 
Therefore, the number of TEBs at a particular 
time point can be altered by changes to the 
extent of growth as well as to the pace of dif­
ferentiation. For example, if the overall num­
ber of ducts is decreased by an environmental 
exposure, then the overall number of TEBs 
in the gland will be decreased compared with 
those in controls at any time point, as demon­
strated for perfluorooctanoic acid (PFOA) 
exposures in mice (White et al. 2009). Some 
reports have not differentiated between 
changes in TEB number due to overall gland 
size and those due to altered develop  mental 
pace. Evaluation at multiple time points and 
consideration of the total number of terminal 
ends, as well as the absolute number of TEBs, 
alleviate this problem and convey the relative 
number of structures.
Steroid hormones. In one of the first studies   
of neonatal exposure to estrogen, progester­
one, or both in mice, Jones and Bern (1979) 
reported irreversible adult MG effects, includ­
ing secretory stimulation, dilated ducts, 
and abnormal lobulo  alveolar develop  ment. 
Perinatal treatment with estrogens such as 
estradiol or diethyl  stilbestrol (DES) has been 
reported to produce accelerated develop  ment, 
characterized by increased pubertal TEB den­
sity, and to promote ductal prolifera  tion dur­
ing the peri  pubertal period in both rats and 
mice (Fielden et al. 2002; Hilakivi­Clarke 
et al. 1997; Hovey et al. 2005; Tomooka 
and Bern 1982; Warner 1976). In addition, 
Doherty et al. (2010) reported that pre  natal 
DES exposure in mice altered expression 
in MG of genes that may be important in 
tumori  genesis. Ovariectomy has been reported 
to diminish or obviate the effect of neo  natal 
ovarian steroids on mouse MG develop  ment 
(Jones and Bern 1979; Mori et al. 1976), and 
strain differences in sensitivity have also been 
reported (Mori et al. 1976; Yang et al. 2009). 
In rats exposed continuously beginning at 
conception, oral ethinyl estradiol exposure 
induced ductal hyper  plasia in male rat MGs 
by PND50, and this effect was less appar­
ent in rats assessed later in life (Latendresse 
et al. 2009). Thus, morphological changes 
in MG reflect timing of exposure as well as 
timing of assessment, and so both of these 
variables must be considered when comparing 
results across studies. Supplemental Material, 
Table 1 (doi:10.1289/ehp.1002864) com­
piles the methods and findings of studies that 
have evaluated the effects of hormone, dietary, 
or chemical exposures during the pre  natal, 
neo  natal, or peri  pubertal periods on MG 
develop  ment up to 10 weeks. Several addi­
tional endocrine­sensitive end points com­
monly assessed to indicate relative sensitivity 
are also included in the table.
In addition, whereas peri  natal steroid hor­
mone exposure alters proliferation and TEB 
number, peri  pubertal exposure that occurs 
after proliferation has begun affects mainly 
the differentiation of TEBs into mature struc­
tures. For example, pubertal DES treatment 
in rats increased the pace of lobule formation 
and decreased the number of terminal ducts 
and TEBs compared with vehicle­treated con­
trols just after puberty (Odum et al. 1999). 
Prepubertal DES treatment of rats (on 
PNDs 23–29) resulted in fewer TEBs, termi­
nal ducts, and alveolar buds, with a concomi­
tant increase in the more differentiated lobules, 
overall suggesting a faster differentiation pace 
(Brown and Lamartiniere 1995). Treatment of 
post  pubertal rodents with steroids or human 
chorionic gonadotropin increases differentia­
tion of the MG in a manner thought to mimic 
develop  ment during pregnancy (Russo and 
Russo 2004b; Sivaraman et al. 1998).
Phytoestrogens. Effects of treatment with 
phyto  estrogens such as genistein are simi­
lar to those observed after estrogen receptor 
agonist exposure; peri  natal exposure can lead 
to increased proliferation, and peri  pubertal 
exposure can lead to accelerated differentia­
tion (reviewed by Warri et al. 2008). For 
example, Hilakivi­Clarke et al. (1998) and 
Padilla­Banks et al. (2006) showed increased 
TEBs after peri  natal genistein treatment, 
and Cotroneo et al. (2002) showed acceler­
ated develop  ment in MG after pre  pubertal 
exposure, as indicated by increased TEBs and 
ductal branching at an early time point, com­
pared with untreated animals. After gesta­
tional and lactational genistein exposure, You 
et al. (2002) observed enhanced glandular dif­
ferentiation at weaning, and males were more 
sensitive to the effect than females. Male rats 
in a multi  generational genistein feeding study 
also showed ductal hyperplasia at PND50, 
a surprisingly early life stage for these effects 
(Latendresse et al. 2009). Effects on MG 
develop  ment have also been observed after 
peri  natal exposure to other phyto  estrogens, 
including zearalanone and resveratrol, and to 
flaxseed [see Supplemental Material, Table 1 
(doi:10.1289/ehp.1002864)].
Environmental chemicals. Altered MG 
develop  ment after peri  natal exposure has also 
been observed for numerous EDCs, including 
atrazine, bisphenol A (BPA), dibutyl  phthalate, 
dioxin, methoxychlor, nonyl  phenol, poly­
brominated diphenyl ethers, and PFOA. 
Changes include delayed MG develop  ment, 
ductal hyperplasia, alveolar hypo  plasia, 
reduced apoptosis in TEBs, altered gene or 
protein expression, increased or decreased 
numbers of terminal ducts or lobules, and 
accelerated alveolar differentiation [see 
Supplemental Material, Table 1 (doi:10.1289/
ehp.1002864)], as well as increased MG 
tumors after carcinogen challenge (Brown 
et al. 1998; Durando et al. 2007; Jenkins et al. 
2007). In addition, late­gestational treatment 
with Ziracin, a candidate anti  bacterial drug, 
induced hypoplasia (ducts without any acinar 
develop  ment) in rats (Poulet et al. 2005).
Critical exposure windows and reversibility. 
Studies of the ubiquitous industrial pollutant 
dioxin and the high­use herbicide atrazine have 
investigated critical periods of exposure associ­
ated with MG effects. Atrazine delayed MG 
develop  ment when exposure occurred around 
GD17–19 but had less of an effect after earlier 
3­day windows, and dioxin exposure at GD15, 
but not after GD19, led to MG under  develop­
ment (Fenton et al. 2002; Rayner et al. 2005). 
More recent studies on the industrial surfactant 
PFOA (White et al. 2009) demon  strate a simi­
lar critical period. The heightened sensitivity 
during this time period is attributed to the 
formation of the mammary bud and initial 
branching that occurs during late pregnancy. Rudel et al.
1056  v o l u m e  119 | n u m b e r 8 | August 2011  •  Environmental Health Perspectives
As discussed above, exposure timing and dose 
influence the pattern of MG changes (Warri 
et al. 2008).
Although numerous studies have shown 
persistent effects on the MG, few have evalu­
ated whether the changes could be revers­
ible. For example, in utero exposure to dioxin, 
Ziracin, PFOA, or BPA led to permanent 
changes in the adult MG (Fenton et al. 2002; 
Poulet et al. 2005; Vandenberg et al. 2007; 
White et al. 2009). In contrast, effects of 
genistein and ethinyl estradiol in male MG 
appeared to reverse after treatment withdrawal 
(Latendresse et al. 2009). It is unclear whether 
the persistence of alterations reflects the bio­
logical half­life and lipophilicity of the chemi­
cal or epigenetic changes, and this may differ 
by compound.
Mechanisms. It is striking that MG 
develop  mental changes have been observed 
after exposure to diverse agents, including 
estrogens, androgens, anti  androgens, thyroid­
active chemicals, and aryl hydro  carbon recep­
tor agonists. Data do not indicate a similar 
mode of action for atrazine, but PFOA, bro­
minated diphenyl ethers, and dioxin all have 
been shown to induce a pheno  typically similar 
response of delayed MG develop  ment after 
neonatal exposures [see Supplemental Material, 
Table 1 (doi:10.1289/ehp.1002864)]. Novel 
mechanisms continue to be discovered. In 
a recent study, Doherty et al. (2010) found 
that in utero exposure of mice to DES or 
BPA increased protein expression and func­
tional activity of the histone methyl  transferase 
enhancer of zeste homolog 2 (EZH2) in the 
MG. EZH2 has been linked to breast cancer 
risk and epigenetic regulation of tumori  genesis. 
Its up­regulation is a potential mechanism 
through which in utero exposure to these 
chemicals may produce epigenetic changes 
leading to increased breast cancer risk (Doherty 
et al. 2010).
Sex differences. The few studies that have 
evaluated effects on male MG have indicated 
that male rats could be more sensitive. For 
example, one study found altered MG in males, 
but not females, treated with methoxy  clor 
during gestation (You et al. 2002), and MG 
effects of genistein and ethinyl estradiol have 
been reported in males at lower doses than in 
females (Delclos et al. 2001; Latendresse et al. 
2009). Study of sex differences in responsive­
ness can provide information about mecha­
nisms of action for the test agents. Although 
male mice lack mammary epithelia, there are 
transgenic mouse models in which mammary 
epithelial growth can be induced in males 
(Li et al. 2002). Mouse models are needed to 
study some chemicals, such as PFOA, whose 
pharmaco  kinetics in mice and humans are 
most similar.
The  Organisation  for  Economic 
Co­operation and Development (OECD) 
guidelines for subchronic oral toxicity test­
ing (OECD 2008) include evaluation of the 
male, but not female, MG as an optional end 
point. In some studies using these guidelines, 
the male MG appears to be among the most 
sensitive end points evaluated (Okazaki et al. 
2001), and at least one such study has found 
it to be the most sensitive end point in males 
(Andrews et al. 2002).
Consequences of Altered 
Mammary Gland Development
Developmental exposures to certain EDCs can 
lead to MG develop  mental effects, lactational 
deficits, or cancer, but little is known about the 
relationships between the develop  mental and 
adult end points. The morphologi  cal changes 
in MG develop  ment, particularly effects on 
TEBs, suggest the potential for functional out­
comes such as lactational insufficiency, altered 
pubertal timing, pre  neoplasia, or increased 
susceptibility to carcinogens (Fenton 2006). 
Table 1 and Supplemental Material, Table 2 
(doi:10.1289/ehp.1002864) show these types 
of effects occurring across rodent and human 
studies for selected compounds for which 
there are data. However, there are data gaps 
regarding the relation  ships among the vari­
ous MG outcomes because a) only a handful 
of chemicals have been studied; b) there has 
not been a standard procedure to assess MG 
develop  mental changes; c) MG assessment in 
multi  generational studies has been limited; 
and d) few studies include full assessment of 
dose response.
Carcinogenesis. Reported changes in 
patterns of breast develop  ment in U.S. girls 
(reviewed by Euling et al. 2008) raise concerns 
about whether earlier onset of breast develop­
ment is associated with breast cancer or other 
adult diseases, because earlier menarche is 
an established risk factor for breast cancer 
(Kelsey et al. 1993). Furthermore, studies in 
humans and rodent models demon  strate that 
hormonal factors that affect MG develop  ment 
also influence susceptibility to carcinogens.
Hormonal factors alter susceptibility to 
carcinogens. Ovarian, pituitary, and placental 
hormones, which vary by life stage and with 
pregnancy events, are important determinants 
of breast cancer susceptibility in humans and 
rodents (Russo and Russo 2004b). In both 
mice and rats treated with chemical carcino­
gens, hormone withdrawal (ovariectomy) 
inhibits tumor develop  ment, whereas hor­
mone supplementation increases the incidence 
of adeno  carcinoma. In humans, removal 
of ovaries by 35 years of age dramatically 
reduces breast cancer risk (Eisen et al. 2005; 
Trichopoulos et al. 1972), and anti  estrogens 
are effective in breast cancer treatment and 
chemoprevention (Vogel et al. 2010).
Susceptibility to carcinogens depends 
on life stage. The influence of life stage on 
susceptibility to carcinogen exposure has 
been demon  strated in rats and humans. For 
example, ionizing radiation is maximally 
potent as a human breast carcinogen when 
exposure occurs during childhood or adoles­
cence (Henderson et al. 2010; Land 1995); 
this observation is consistent with findings in 
rodents (Imaoka et al. 2009). The increased 
tumor response from carcinogen exposure 
early in life is attributed to the presence of 
proliferating and undifferentiated structures 
such as TEBs, which are present during the 
pubertal mammary epithelial expansion and 
display elevated DNA synthesis compared 
with other MG structures (Kleinberg et al. 
2009). TEBs are considered the most vulner­
able MG target structure for carcinogen expo­
sure (Medina 2007; Russo and Russo 1996). 
In animals and humans, tumor response from 
carcinogen exposure is highest when expo­
sure occurs during adolescence, when TEBs 
are still abundant (Henderson et al. 2010; 
Imaoka et al. 2009; Land 1995; Russo and 
Russo 2004b). As a result, there is concern 
that exposures to xeno  biotics that increase the 
number or longevity of proliferating TEBs 
Table 1. Female MG outcomes after developmental environmental exposures: rodent–human concordance 
for selected agents. 
Human study MG outcomes Animal study MG outcomes
Environmental factor Development Lactation
Cancer 
risk Development Lactation
Cancer 
susceptibility
Hormonal milieu:  
dosing (animals) or 
surrogates (humans)
Δ Δ Δ Δ Δ (EE2-dams),a  
— (EE2-offspring)b 
Δ
DES Δc  Δ Δ (Dams) Δ
Genistein/soy Δ Δ Δ Δ (Dams)
Δ (Offspring) Δ
DDT/DDE Δc  Δ Δ – (Dams)
Dioxins/furans Δ Δd  Δ Δ (Dams) Δ
Abbreviations: —, no effect on this end point; Δ, at least one study has reported an association between the exposure 
and altered outcomes [see details and citations in Supplemental Material, Table 2 (doi:10.1289/ehp.1002864)]; DDE, 
dichloro  diphenyl  dichloro  ethylene; DDT, dichloro  diphenyl  trichloro  ethane; DMBA, dimethylbenzanethrene; EE2, ethinyl-
estradiol. Examples of concordance between rodents and humans for MG effects are included here. In some cases, 
findings are mixed or conflicting; in human studies, exposure measures are often imprecise.
aLactation effect in animals dosed continuously or during pregnancy and/or lactation. bLactation effect in animals dosed 
only in utero and/or preweaning. cConflicting findings. dExposure may not have been during early life/development.EDCs and altered mammary gland development
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might increase susceptibility to breast cancer 
(Birnbaum and Fenton 2003; Fenton 2006). 
After the pubertal growth spurt and through­
out adult life, it is the terminal ductal struc­
tures that give rise to breast cancers (Kleinberg 
et al. 2009; Medina 2007; Russo and Russo 
2004b). During pregnancy, differentiation 
of terminal structures increases, and this dif­
ferentiation has been hypothesized to account 
for lower MG sensitivity to carcinogens post­
pregnancy (Russo and Russo 2004b).
Early life exposures to (non  carcinogenic) 
chemicals may affect response to carcinogens 
in later life. Experimental models involving 
carcinogen challenge have been used widely to 
demon  strate that hormones and growth factors 
influence MG develop  ment, differentiation, 
and carcino  genesis; these models could read­
ily be extended to evaluate increased cancer 
risk from early life environmental exposures. 
These models have been used, for example, to 
investigate potential chemo  preventive agents 
that accelerate MG differentiation (e.g., by 
mimicking pregnancy hormones) and decrease 
tumor susceptibility (Cotroneo et al. 2002; 
Kleinberg et al. 2009; Russo and Russo 1996). 
Rodent models used in these studies include 
dimethylbenz[a]anthracene (DMBA) and 
nitroso  methyl  urea (NMU) challenge in rats 
and mice, and the mouse mammary tumor 
virus (MMTV) model. More recently, geneti­
cally modified mouse models have been used 
to study mammary tumors that are com­
parable with human breast tumors in their 
latency, histo  types, and endocrine respon­
siveness (Cardiff et al. 2000; Kamiya et al. 
1995; Medina 2007; Russo and Russo 2004b; 
Thompson and Singh 2000).
In rodents, early life exposure to hormon­
ally active agents affects MG tumor formation 
in carcinogen­challenge models. For example, 
neonatal estrogen (or androgen) treatment 
of mice (MMTV model) or rats (DMBA 
model) induced MG develop  mental changes 
and increased tumors (Lopez et al. 1988; 
Mori et al. 1976, 1979). In addition, early life 
exposures to genistein (Hilakivi­Clarke et al. 
1998, 1999), alcohol (Hilakivi­Clarke et al. 
2004), dioxin (Brown et al. 1998; Desaulniers 
et al. 2001; Jenkins et al. 2007), and oral BPA 
(Jenkins et al. 2009) caused increased MG 
tumor multi  plicity and decreased latency after 
DMBA challenge at PND50. These effects 
were accompanied by altered MG develop­
ment observed in whole mounts (genistein, 
alcohol, dioxin) or altered protein expression 
(BPA). Lifetime exposures (beginning pre­
natally) to genistein, ethinyl estradiol, and 
BPA have been reported to alter MG develop­
ment and increase incidence of pre  neoplastic 
lesions in the MG, with a stronger effect in 
early adulthood than at 2 years of age, when 
MG histopathology is typically performed 
(Latendresse et al. 2009; Murray et al. 2007; 
Vandenberg et al. 2008). Short­term genistein 
treatment during the peri  pubertal period 
reduces MG tumors after carcinogen chal­
lenge, whereas peri  natal or lifetime exposure 
seems to increase them, although studies are 
not consistent (reviewed by Warri et al. 2008). 
Similarly, both gestational (Brown et al. 1998) 
and pre  pubertal (Desaulniers et al. 2001) 
dioxin exposure caused increased MG tumors 
after carcinogen challenge, whereas later life 
exposure decreased spontaneous MG tumors 
(Kociba et al. 1978).
In humans, maternal factors that affect 
the fetal hormone environment also appear 
to affect later breast cancer risk in daughters, 
possibly by imprinting the developing MG, 
thereby altering future tissue responsiveness to 
hormonal stimulation (e.g., altering estrogen 
receptor levels or sensitivity) or to geno  toxic 
insult (e.g., by increasing cell proliferation or 
diminishing differentiation). The hypothe  sis 
that in utero endocrine­related factors influ­
ence breast cancer risk of a daughter is sup­
ported by epidemiology studies that have 
found a) pre  eclampsia associated with reduced 
breast cancer risk in offspring and b) high 
birth weight correlated with higher breast can­
cer risk (Hoover and Troisi 2001; Troisi et al. 
2007; Xue and Michels 2007). In addition, 
there is some evidence that in utero exposure 
to DES is associated with higher breast cancer 
risk in women [Palmer et al. (2006); however, 
Verloop et al. (2010) did not find an associa­
tion] and with increased MG tumor incidence 
in rats (Rothschild et al. 1987). Furthermore, 
the single epidemiologic study of the EDC 
dichloro  diphenyl  trichloro  ethane (DDT) that 
used prospective meas  ures of adolescent/young 
adult exposure in relation to breast cancer risk 
(Cohn et al. 2007) found significant associa­
tions, whereas many studies in which DDT 
or its metabolite dichloro  diphenyl  dichloro­
ethylene (DDE) were meas  ured in older 
women did not observe an association with 
breast cancer. 
Pregnancy is another critical window cor­
responding to a time of extensive MG pro­
liferation and differentiation. DES exposure 
in pregnant women has been associated with 
increased breast cancer risk in the mother 
as well as her daughter (Titus­Ernstoff et al. 
2001). A study of DMBA­challenged rats 
fed a high­fat diet during pregnancy showed 
an increase in circulating estrogen during 
pregnancy and increased mammary tumors 
(Hilakivi­Clarke et al. 1996).
Lactation. The American Association of 
Pediatrics (AAP) recommends that all infants 
receive breast milk during the first 6 months 
(AAP 1997) and, further, that they are fed 
breast milk exclusively during this time (AAP 
2005), because of the numerous demon  strated 
benefits of breast­feeding. Although data are 
limited, reports estimate that 3–6 million 
mothers are unable to produce milk or have 
difficulty breast­feeding each year (Lew et al. 
2009). The reasons for this remain unclear, 
especially given that lactation insufficiency can 
be the result of psycho  social as well as biologi­
cal factors. However, environ  mental chemicals 
are one candidate explanation for inability to 
initiate and/or sustain breast­feeding (Neville 
and Walsh 1995).
Impaired lactation may be associated with 
altered MG develop  ment (decreased or unre­
sponsive breast tissue) and/or endocrine disrup­
tion (improper hormonal support for lactation). 
Critical windows include pregnancy and lac­
tation as well as puberty and the prenatal/ 
perinatal period. As such, exposure to an EDC 
during pregnancy has the potential to disrupt 
lactation in the mother and the daughter. In 
human studies, strong early findings of asso­
ciations between serum DDE and shortened 
lactation in two populations have been only 
partly replicated, and few other agents have 
been studied (Cupul­Uicab et al. 2008; Gladen 
and Rogan 1995; Rogan et al. 1987). In 
rodents, impaired lactation has been observed 
in conjunction with altered MG develop  ment 
in one or more genera  tions after gestational 
exposure to dioxin (Vorderstrasse et al. 2004), 
PFOA (White et al. 2007, 2009), atrazine 
(Rayner et al. 2005), BPA (California Office 
of Environmental Health Hazard Assessment 
2009; Matsumoto et al. 2004), genistein 
[National Toxicology Program (NTP) 2008], 
and the candidate pharma  ceutical Ziracin 
(Poulet et al. 2005). For example, atrazine fed 
to rats during gestation induced MG develop­
mental changes in offspring, characterized by 
stunted develop  ment, and when these rats were 
bred, their offspring (second­generation) had 
significantly reduced weight gain, suggesting 
insufficient milk production (Rayner et al. 
2005). In an example of effects on lactation in 
the dam, exposure of pregnant mice to PFOA 
decreased pup weight and survival, dimin­
ished differentiation/growth of dam MG, and 
induced some alterations in gene expression 
for milk proteins, which taken together suggest 
effects on lactation in the exposed dams (White 
et al. 2007, 2009).
Treatment during pregnancy has the 
potential to affect lactation in both the dam 
and offspring. Impaired lactation in the dams 
is typically identified because of decreased 
pup weight or survival, and impaired lactation 
in the offspring can be determined only in 
multi  generational studies where offspring are 
followed through successful reproduction and 
lactation (Makris 2011). The rodent models 
and assessment methods used in guideline 
studies are not adequate for identifying effects 
on lactation because the surrogate markers 
of pup weight and post  natal survival are not 
sensitive or specific indicators of impaired 
lactation (Makris 2011).Rudel et al.
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Human Health Risk 
Assessment Issues
MG assessment in chemical test guidelines. 
MG develop  ment can be affected after early 
exposure to EDCs in rodents. However, few 
guideline studies for testing environ  mental 
chemicals include pre  natal or early life dosing, 
and MG end points are limited primarily to 
indirect or surrogate observations during lacta­
tion and to clinical and pathological evaluation 
of adult mammary tissue (Makris 2011). For 
example, the standard 2­year rodent cancer 
bio  assay, initiating treatment in young adult 
animals, is likely to be less sensitive to car­
cinogens than if develop  mental exposures were 
used, and it cannot provide information on 
altered susceptibility to carcinogens induced 
by early life exposures affecting MG develop­
ment (Hovey et al. 2002; Medina 2007; Rudel 
et al. 2007; Russo and Russo 2004b; Singh 
et al. 2000; Thayer and Foster 2007).
To strengthen MG assessment and chemi­
cal testing, it is a priority to enhance histo­
pathological evaluation of MG develop  ment 
(e.g., using longitudinal rather than trans­
verse sectioning so that a larger tissue plane 
is evaluated), increase attention to evaluation 
of male MG tissue, and incorporate early life 
exposures in rodent subchronic and chronic/
carcinogenicity studies. Consistent with 
these recommendations, the NTP has begun 
including gestational and lactational dosing 
in rats assigned to subchronic and carcinoge­
nicity studies and is taking steps to include 
early life male and female MG whole­mount 
preparations and longitudinal MG sectioning 
in reproductive assessment and cancer studies 
(NTP 2010; Thayer and Foster 2007). Use of 
these expanded protocols will facilitate link­
ing altered MG develop  ment with later life 
outcomes.
As a potential addition to some toxicity 
test guidelines, MG whole­mount assessment 
can demon  strate morphological changes in 
develop  ment and differentiation and define 
the temporal and spatial progression of epithe­
lial develop  ment. Another important reason 
to include MG assessments in screening­level 
toxicology studies is to ensure that MG effects 
are identified and can be evaluated in more 
comprehensive studies. Specifically, data gen­
erated using whole mounts may be used to 
trigger further assessment, such as: a) section­
ing tissue blocks, b) evaluating subsequent 
(e.g., F1) generations for lactational impair­
ment, c) maintaining a population longer on 
study for spontaneous neoplasia evaluation, or 
d) evaluating altered tumor susceptibility using 
a carcinogen­challenge protocol. Furthermore, 
a whole mount may be the only indication 
of abnormal develop  ment in the male MG, 
which is sensitive to very low doses in some 
studies (Delclos et al. 2001; Latendresse 
et al. 2009). However, currently there are no 
standardized whole­mount procedures, and 
consideration of these data in chemical risk 
assessment has been limited. The OECD test 
guideline for an extended one­generation 
reproductive toxicity study (OECD 2010) 
could be revised to include assessment of MG 
develop  ment using whole mounts and/or more 
thorough histopathology (Hvid et al. 2010). In 
addition, MG assessment of males and females 
could be added to the U.S. EPA Endocrine 
Disruptor Screening Program (EDSP) puber­
tal develop  ment protocols (U.S. EPA 2009a, 
2009b). MG develop  mental assessment could 
also be extended to include females in the 
OECD Test Guideline 407 pubertal protocol 
(OECD 2008). 
Adding MG whole­mount procedures 
to EDSP or OECD test guidelines has raised 
concerns that a) these assays could be redun­
dant to endocrine­sensitive end points assessed 
[e.g., ano  genital distance, timing of vaginal 
opening (VO), circulating hormones, and 
estrous cyclicity], and b) that the procedure is 
too difficult to be consistently executed across 
laboratories. However, in some cases MG 
effects have been observed at lower doses than 
other EDC outcomes (Table 2), and there is 
concern that EDSP assays, which identify 
chemicals affecting estrogen, androgen, or thy­
roid activities, may not be sensitive to the many 
mechanisms that can affect breast develop­
ment. It is reasonable, therefore, to include the 
MG whole mount in screening studies, at least 
on a provisional basis, to see if the information 
gathered is redundant or unique.
Human relevance of rodent models. 
Rodent models have been widely used to 
charac  terize the influence of susceptibility 
factors (e.g., ovarian, pituitary, and placental 
hormones; life­stage and reproductive events) 
on malignant transformation of the MG, and 
parallels between rodent and human MG 
structures and pathologies have been enumer­
ated (Medina 2007; Russo and Russo 2004b; 
Singh et al. 2000). Although a few findings in 
the context of chemicals testing have gener­
ated concern about human relevance (reviewed 
by Rudel et al. 2007), an extensive body of 
breast cancer research demon  strates similarities 
between rodent and human MG develop  ment 
and carcino  genesis. These studies indicate that 
rodent mammary tumors mimic the diver­
sity of human breast cancers with respect to 
important initiation processes, histo  pathology, 
hormone dependence, and host–target cell 
intera  ctions (Boylan and Calhoon 1983; 
Imaoka et al. 2009; Medina 2007; Rudland 
et al. 1998; Russo et al. 2000; Russo and 
Russo 1993, 2004a; Singh et al. 2000). In 
Table 2. MG as a sensitive end point of endocrine disruption after developmental exposures in rodents.a
Compound Study Species, exposure timing MG effect typeb MG effect LOEL Basis for inclusionc
Females
BPA Jenkins et al. 2009 Rat, postnatal (lactation) Proliferationd 250 μg/kg/day No effects on age of VO, body weight, serum 
progesterone, or serum estradiol at 250 μg/kg/day 
(highest dose tested) 
Murray et al. 2007 Rat, prenatal Hyperplasiae 2.5 μg/kg/day No effects on body weight, age of VO, litter size, or sex 
ratio at this or higher doses (2.5–1,000 μg/kg/day).
Muñoz-de-Toro et al. 2005 Mouse, perinatal Morphologyf, proliferationd 25 ng/kg/day No effects on plasma estradiol at first proestrus at this or 
higher dose (250 ng/kg/day)
DDT Brown and Lamartiniere 
1995
Rat, peripubertal Proliferationd 50 ng/kg/day Single-dose study; no effects on body weight or uterine-
ovarian weight
Genistein Fritz et al. 1998 Rat, prenatal and 
postnatal
Morphologyf 25 mg/kg/day No effects on body weight, uterine weight, AGD, estrous 
cyclicity, or age at VO at this or higher dose (250 mg/
kg/day)
Padilla-Banks et al. 2006 Mouse, neonatal Morphologyf 0.5 mg/kg/day Effects on ability to deliver live pups and estrous cyclicity 
at 50 mg/kg/day (but not at either 0.5 or 5 mg/kg/day)
Males
Genistein Delclos et al. 2001 Rat, prenatal and 
postnatal
Sizeg; hyperplasiae 25 ppm Effects on ventral prostate weight, pituitary weight, age 
of eye opening and age of ear unfolding at 1,250 ppm
Abbreviations: AGD, anogenital distance; LOEL, lowest observed effect level. 
aFor inclusion, a study must have assessed other end points in addition to MG; findings are based on statistically significant effects observed. bAll effects are relative to negative 
controls; effects on protein or gene expression are omitted. For more detail, see Supplemental Material, Table 1 (doi:10.1289/ehp.1002864). cSee articles for further study methods 
and results. dChanges in markers of proliferation/mitotic activity (e.g., cell cycle marker proliferating cell nuclear antigen, cell number). eChanges in numbers or sizes of hyperplastic 
  structures. fChanges in numbers/ratios of structures, branching, and so on for given developmental stage. gChanges in the area or weight of gland. EDCs and altered mammary gland development
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general, research indicates greater cross­species 
similarities for MG develop  ment and cancer 
than for human menstrual and rodent estrous 
cyclicity or for human puberty and rodent 
VO—end points currently included in many 
EDC test protocols (U.S. EPA 2011).
An expert panel on MG tumors con­
cluded that existing rodent models are use­
ful as screening tools for identifying potential 
breast carcinogens (Thayer and Foster 2007). 
Further, the majority of chemicals that are 
positive for mammary tumors in the rodent 
cancer bio  assay have some evidence of geno­
toxicity and many are multi    site carcinogens, 
supporting relevance to humans (Rudel et al. 
2007). Although there are many similarities 
in the hormonal control of lactation across 
species, less is known about the utility of the 
rodent as a model for predicting chemical 
effects on human lactation. In any case, many 
risk assessment guidelines operate on the prin­
ciple that animal effects are considered relevant 
to humans in the absence of data to indicate 
otherwise (U.S. EPA 1991, 1996, 2005).
A related issue is the consideration of 
carcinogen­challenge models as indicators of 
altered carcinogen susceptibility. DMBA and 
NMU are primary breast­specific carcino­
gens that have been widely used in experi­
ments designed to assess the alteration of the 
tumor response by hormones or other factors 
(Kamiya et al. 1995; Medina 2007; Singh 
et al. 2000). Despite the long­standing use 
of such carcinogen challenge experiments to 
assess effects of hormonal or develop  mental 
alterations on tumor susceptibility, the pro­
tocols are not common in chemical toxicity 
assessment. Risk assessors have not considered 
data from carcinogen challenge experiments 
because of concerns about the protocol rep­
resenting a chemical mixture study and about 
the presumed lack of relevance of DMBA 
or NMU exposure to humans. However, a 
number of consistent findings of increased 
susceptibility have been observed in human 
and rodent studies across multiple MG end 
points for endogenous hormonal factors, 
DES, genistein, and dioxin, among others 
(Table 1). Models that consider the inter­
active effects of endogenous hormones and 
carcinogenic factors across multiple life stages 
are likely to be more relevant to human health 
than those with simpler design, because they 
better reflect the human experience.
Relative sensitivity of MG effects. A lim­
ited set of studies provide evidence that MG 
alterations may be more sensitive to some 
EDCs than are other hormonally responsive 
end points (Table 2). To precisely determine 
the relative sensitivity of EDC effects requires 
studies that include MG as part of a larger set 
of endocrine­sensitive end points. Of the stud­
ies that simultaneously evaluated MG mor­
phology and at least one other EDC­sensitive 
end point after develop  mental dosing, a subset 
has detected effects on the MG at dose levels 
or during exposure periods that did not elicit 
observable changes in other end points.
Adversity of MG develop  mental changes. 
Hormonal factors either increase or decrease 
MG tumor susceptibility, and both transient 
and permanent effects have been observed on 
MG develop  ment. This raises the question 
of what types of alterations to MG develop­
ment should be considered adverse. In the 
context of regulatory evalua  tion of chemicals, 
one point of view is that MG develop  mental 
changes reflect altered growth and develop­
ment, effects considered adverse by the U.S. 
EPA Developmental Toxicity Risk Assessment 
Guidelines (U.S. EPA 1991). For com­
parison, there is also controversy in the risk 
assessment community about whether other 
common markers of altered pubertal timing 
(e.g., VO, pre  putial separation) have human 
relevance. These end points have never  the  less 
been considered adverse, as they are respon­
sive to endogenous sex steroids, which are 
important regulators of sexual develop  ment 
conserved across mammalian species. By this 
reasoning, altered MG growth and develop­
ment, which is known to have human rele­
vance, should be considered adverse as well. 
The question of adversity was discussed by 
experts gathered at the workshop in the con­
text of risk assessment. In spite of the out­
standing questions, the majority perspectives 
among experts advance the view that MG 
develop  ment and subsequent effects represent 
a public health outcome of concern and are 
a priority for future research and assessment. 
Priority questions, current views, and out­
standing issues for risk assessment are sum­
marized in Table 3.
An important question is whether MG 
develop  mental alterations are plausibly related 
to increased tumor susceptibility by a) epi­
genetic imprinting of tissue, b) alteration of 
stem cell populations, or c) increased num­
ber or ontological duration of TEBs or other 
structures known to be more vulnerable to 
carcinogens. Some experts suggest that such 
agents should themselves be considered 
carcino  gens. Indeed, the International Agency 
for Research on Cancer (IARC) deems an 
agent carcinogenic if it is “capable of increas­
ing the incidence of malignant neoplasms, 
reducing their latency, or increasing their 
severity or multi  plicity” (IARC 2006). The 
U.S. EPA defines an effect as adverse if it 
“reduces the organism’s ability to respond 
to an additional environmental challenge” 
(U.S. EPA 2010). Applying these defini­
tions, compounds that cause cancer, either 
alone or in combination with other factors 
at a variety of points in a biological chain 
of events leading to tumor formation, may 
reasonably be considered carcinogens, includ­
ing chemicals that increase susceptibility to 
cancer. Even if such agents are not designated 
as carcinogens, their profound impacts should 
encourage the risk assessment community to 
consider the increase in cancer susceptibility 
as an adverse effect and therefore to charac­
terize doses required to elicit the effect. In 
any case, applying this approach to risk assess­
ment requires a better under  standing of the 
relation  ship between altered MG develop­
ment and carcino  gen susceptibility.
Conclusions and Research 
Recommendations
Research demonstrates many similari­
ties between humans and rodents in nor­
mal and perturbed MG develop  ment and 
carcino  genesis. In both humans and rodents, 
develop  mental exposure to hormones affects 
MG develop  ment and carcinogen suscep­
tibility, and these findings are the basis 
for on  going research to identify chemo­
preventative agents in humans and to deter­
mine how EDCs may alter breast cancer 
risk, pubertal timing, or lactation. EDCs 
with diverse mechanisms of action, including 
many not considered primarily estrogenic, 
alter MG develop  ment in rodents. In some 
Table 3. Priority questions, current views, and issues for improving risk assessment for MG effects.a 
Priority question for risk assessment application Current views  Outstanding issues
Are the rat and mouse adequate models for human 
MG development?
Current knowledge suggests that the rat and mouse are 
reasonable surrogates.
Lack of information about human pubertal development; 
mechanisms may differ among species.
What is the sensitivity of MG developmental effects? In utero exposure in some studies leads to developmental 
effects at doses similar to or lower than other 
developmental and reproductive end points.
Few EDC studies assess both MG development and another 
sensitive end point of ED; there is a lack of human data 
to address dose response and a lack of standardized MG 
development protocol and assessment criteria.
Are MG developmental changes adverse? These changes in MG are considered adverse because they 
represent alterations in growth and developmentb and 
may be a risk factor for lactation and/or cancer outcomes.
Varied definitions of “adversity,” depending on scientific 
discipline and context.
aBased on the majority viewpoint of the experts at the Mammary Gland Evaluation and Risk Assessment Workshop. bAccording to guidance from the U.S. EPA (1991, 1996).Rudel et al.
1060  v o l u m e  119 | n u m b e r 8 | August 2011  •  Environmental Health Perspectives
cases, altered MG develop  ment can be the 
most sensitive endocrine end point.
The lack of consistent methods for eval­
uating and reporting MG changes makes it 
difficult to compare findings across studies, 
hindering consideration of MG develop  mental 
effects in risk assessment. Continued prog­
ress will require consistent approaches across 
laboratories, along with a discussion of unique 
findings and unanticipated effects. In addition, 
the relation  ships between altered develop  ment 
and effects on lactation or carcino  genesis are 
still being defined. Addressing these research 
needs [detailed in Supplemental Material 
(doi:10.1289/ehp.1002864)] is a priority, and 
enhanced chemical testing and risk assessment 
are needed to characterize these effects.
Major research initiatives under way 
include The National Children’s Study, which 
has a number of EDC hypotheses proposed 
for testing in its longitudinal study (Lewin 
Group 2003), and the NIEHS Breast Cancer 
and the Environment Research Centers 
(NIEHS 2010), which have on  going human 
studies focusing on the relationship between 
environmental exposures and age of breast 
develop  ment onset and which also support 
experi  mental animal research in this area. 
Research priorities identified at the workshop 
[provided in detail in Supplemental Material 
(doi:10.1289/ehp.1002864)] include further 
develop  ment and validation of the MG whole­
mount protocol, research to establish the 
relation  ship between effects on MG develop­
ment and later life outcomes, and issues rele­
vant to use of these data in risk assessment.
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